This January, the Food and Drug Administration approved the drug Leqembi to treat Alzheimer’s disease. Leqembi is pathbreaking in two ways. First, while the vast majority of Alzheimer’s drugs can only help slow the progress of the disease, Leqembi can stop and reverse cognitive decline. As an FDA news release states, “This treatment option is the latest therapy to target and affect the underlying disease process of Alzheimer’s, instead of only treating the symptoms of the disease.”
Second, Leqembi is one of only two drugs approved by the FDA to treat Alzheimer’s in the past 17 years. The other one, Aduhelm,
